Angiotensin receptor-neprilysin inhibitors: a new paradigm in heart failure with reduced ejection fraction

Docherty, K. F. and McMurray, J. J.V. (2019) Angiotensin receptor-neprilysin inhibitors: a new paradigm in heart failure with reduced ejection fraction. International Journal of Cardiology, 281, pp. 179-185. (doi: 10.1016/j.ijcard.2018.05.124) (PMID:29891240)

164401.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.



Despite significant advances in the last 30 years in reducing morbidity and mortality from heart failure with reduced ejection fraction (HFrEF) with pharmacological and device-based therapies, patients remain at a high risk of adverse cardiovascular outcomes. Sacubitril/valsartan, a first-in-class angiotensin receptor-neprilysin inhibitors (ARNI), has been shown to reduce the risk of cardiovascular death or heart failure hospitalisation and improve symptoms in patients with chronic, ambulatory, symptomatic HFrEF in a large, phase 3, multicentre, international, randomised controlled trial, PARADIGM-HF, when compared to the gold-standard angiotensin converting enzyme inhibitor, enalapril. This article will review the development of sacubitril/valsartan, the evidence for its use and its current and future role in the management of HFrEF.

Item Type:Articles
Keywords:Angiotensin receptor-neprilysin inhibitor, heart failure, heart failure with reduced ejection fraction, natriuretic peptides, neprilysin, renin-angiotensin aldosterone system.
Glasgow Author(s) Enlighten ID:Docherty, Dr Kieran and McMurray, Professor John
Authors: Docherty, K. F., and McMurray, J. J.V.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:International Journal of Cardiology
ISSN (Online):1874-1754
Published Online:02 June 2018
Copyright Holders:Copyright © 2018 Elsevier B.V.
First Published:First published in International Journal of Cardiology 281: 179-185
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
3008570Effect of sacubitril/valsartan compared to valsartan on left ventricular remodelling in patients with asymptomatic left ventricular systolic dysfunction after myocardial infarctionJohn McMurrayBritish Heart Foundation (BHF)PG/17/23/32850CAMS - Cardiovascular Science